JP6983075B2 - 極性の組換え延長部を有するインスリン - Google Patents

極性の組換え延長部を有するインスリン Download PDF

Info

Publication number
JP6983075B2
JP6983075B2 JP2017562721A JP2017562721A JP6983075B2 JP 6983075 B2 JP6983075 B2 JP 6983075B2 JP 2017562721 A JP2017562721 A JP 2017562721A JP 2017562721 A JP2017562721 A JP 2017562721A JP 6983075 B2 JP6983075 B2 JP 6983075B2
Authority
JP
Japan
Prior art keywords
human insulin
insulin
desb30 human
desb30
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017562721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527288A5 (OSRAM
JP2018527288A (ja
Inventor
トマス・バアウロム・ケルスン
トマス・ホウ−イェンセン
ティネ・ニガール・ヴィンター
フランティセク・フバレク
イングリッド・ペテルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2018527288A publication Critical patent/JP2018527288A/ja
Publication of JP2018527288A5 publication Critical patent/JP2018527288A5/ja
Priority to JP2021070977A priority Critical patent/JP2021119156A/ja
Application granted granted Critical
Publication of JP6983075B2 publication Critical patent/JP6983075B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017562721A 2015-06-02 2016-06-02 極性の組換え延長部を有するインスリン Expired - Fee Related JP6983075B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021070977A JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15170337.8 2015-06-02
EP15170337 2015-06-02
EP15176207.7 2015-07-10
EP15176207 2015-07-10
PCT/EP2016/062514 WO2016193380A1 (en) 2015-06-02 2016-06-02 Insulins with polar recombinant extensions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021070977A Division JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Publications (3)

Publication Number Publication Date
JP2018527288A JP2018527288A (ja) 2018-09-20
JP2018527288A5 JP2018527288A5 (OSRAM) 2019-05-09
JP6983075B2 true JP6983075B2 (ja) 2021-12-17

Family

ID=56098249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562721A Expired - Fee Related JP6983075B2 (ja) 2015-06-02 2016-06-02 極性の組換え延長部を有するインスリン
JP2021070977A Withdrawn JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021070977A Withdrawn JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Country Status (6)

Country Link
US (1) US11208452B2 (OSRAM)
EP (1) EP3303380B1 (OSRAM)
JP (2) JP6983075B2 (OSRAM)
CN (1) CN107743494B (OSRAM)
ES (1) ES2784603T3 (OSRAM)
WO (1) WO2016193380A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
LT3551209T (lt) 2016-12-09 2021-09-10 Akston Biosciences Corporation Insulino-fc suliejimai ir panaudojimo būdai
EP3606560A2 (en) * 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
ES2929416T3 (es) * 2018-06-21 2022-11-29 Novo Nordisk As Nuevos compuestos para el tratamiento de la obesidad
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3655006B1 (en) 2018-06-29 2021-11-17 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021136223A1 (en) * 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
SI3972987T1 (sl) 2020-04-10 2023-10-30 Akston Biosciences Corporation Antigen-specifična imunoterapija za covid-19 fuzijske proteine in postopki za uporabo
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP3915571A1 (en) * 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
KR20230083294A (ko) * 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN115716877B (zh) * 2022-07-04 2023-09-01 北京惠之衡生物科技有限公司 一种表达glp-1和胰岛素缀合物多肽的重组工程菌
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286509C (OSRAM)
DE257197C (OSRAM)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
DD257197A1 (de) 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DD286509A5 (de) 1989-06-30 1991-01-31 Veb Berlin-Chemie,De Verfahren zur herstellung von aktivitaetsstabilisierten, wirkungsverlaengerten rektal applizierbaren insulinpraeparationen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
DE69635026T2 (de) 1995-09-21 2006-05-24 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
AU5065198A (en) 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
AU7873798A (en) 1996-12-20 1998-07-17 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002055532A2 (en) 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
EP1444262A2 (en) 2001-11-12 2004-08-11 University of Wales College of Medicine Growth hormone variations in humans and their uses
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1682583T3 (da) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP5735194B2 (ja) * 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
ZA200707006B (en) * 2005-01-25 2008-11-26 Cell Therapeutics Inc Conjugates of biologically active proteins having a modified in vivo half-life
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
KR20070108180A (ko) 2005-02-16 2007-11-08 노보 노르디스크 에이/에스 구조적으로 잘 정의된 분지형 중합체와 콘쥬게이트된인슐린분비제 유도체
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8492129B2 (en) 2005-12-12 2013-07-23 Innova Biosciences, Ltd. Production of conjugates
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
EP2094728B1 (en) 2006-10-26 2013-04-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
EP3173484B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
KR20170116193A (ko) 2008-06-20 2017-10-18 노파르티스 아게 응집이 감소된 면역글로불린
US20110119848A1 (en) 2008-07-02 2011-05-26 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
PE20110221A1 (es) 2008-07-23 2011-04-06 Hanmi Science Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales
EP3178835B1 (en) * 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
EA201290241A1 (ru) 2009-10-29 2013-02-28 Янссен Байотек Инк. Изменение гликозилирования антител
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AU2011254564B2 (en) 2010-05-21 2014-03-27 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US9783571B2 (en) 2011-04-05 2017-10-10 Warham Lance Martin Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
WO2016042093A1 (en) 2014-09-17 2016-03-24 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
CN107810202A (zh) 2015-02-17 2018-03-16 韩美药品株式会社 长效胰岛素或胰岛素类似物复合物
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
CN114939174B (zh) 2015-08-14 2024-06-28 荣昌生物制药(烟台)股份有限公司 抗体-药物偶联物的共价连接子及其制备方法与应用
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates

Also Published As

Publication number Publication date
US11208452B2 (en) 2021-12-28
CN107743494B (zh) 2022-04-29
ES2784603T3 (es) 2020-09-29
JP2021119156A (ja) 2021-08-12
EP3303380A1 (en) 2018-04-11
EP3303380B1 (en) 2020-01-15
JP2018527288A (ja) 2018-09-20
WO2016193380A1 (en) 2016-12-08
CN107743494A (zh) 2018-02-27
US20180291076A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
JP6983075B2 (ja) 極性の組換え延長部を有するインスリン
RU2684456C2 (ru) Новые производные инсулина и их применение в медицине
JP2021177779A (ja) 新規インスリン誘導体及びその医学的使用
US20090069216A1 (en) Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
KR20090071561A (ko) 프로테아제 내성 인슐린 유사체
JPH11502110A (ja) インスリン誘導体
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物
EP3642338A1 (en) Fusion protein with half-life extending polypeptide
US20200283493A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
JP6995284B2 (ja) 新規インスリン類似体およびそれらの使用
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
JP6013330B2 (ja) 追加のジスルフィド結合を含有するヒトインスリン
JP2018531899A (ja) 新規インスリン誘導体及びその医学的使用
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ）
EP1654283A1 (en) Improved method of purifying tfpi and tfpi analogs
JP2022533066A (ja) ポリペプチド誘導体およびその調製方法
Liang et al. Purification and Activity Evaluation of a Novel Thrombopoietin Mimetic Peptide
EA049440B1 (ru) Новые аналоги инсулина и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210427

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211122

R150 Certificate of patent or registration of utility model

Ref document number: 6983075

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees